🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07372963
Starting soon Observational

18F-FAPI PET in Cancers of Unknown Primary Site

NCT07372963 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Zhejiang University
Phase
Observational
Started
2026-02-01
Last updated
2026-01-28

Condition(s) studied

Cancer of Unknown Primary Site

Investigational drug(s) / intervention(s)

18F-FAPI PET

18F-FAPI PET: 18F-FAPI-04 PET/CT

Study summary

This study aims to evaluate the diagnostic efficacy, therapeutic assessment, prognostic analysis, and impact on clinical treatment decisions of 18F-FAPI PET/CT in patients with cancer of unknown primary.

Eligibility

Sex
ALL
Min age
20 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients with clinical or imaging suspicion of cancer of unknown primary origin. 2. Patients with 18F FAPI PET scans. Exclusion Criteria: 1. Concurrent presence of other active malignant tumors or a history of other malignant tumors within the past 5 years; 2. Severe uncontrollable diseases or active infections; 3. Ineligible participants for project informed consent. 4. Pregnant and lactating women.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang

More First Affiliated Hospital of Zhejiang University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07372963 on ClinicalTrials.gov ↗ ← All trials in China